We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
This Quarter
Est. Return
+76.98%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.52B
AUM Growth
+$1.17B
(+50%)
Cap. Flow
+$333M
Cap. Flow
% of AUM
9.47%
Top 10 Holdings %
Top 10 Hldgs %
65.35%
Holding
41
New
13
Increased
13
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$95.9M |
| 2 |
Genmab
GMAB
|
+$93M |
| 3 |
UroGen Pharma
URGN
|
+$75.7M |
| 4 |
CDTX
Cidara Therapeutics
CDTX
|
+$61.3M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$57.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$85.3M |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$84.2M |
| 3 |
Disc Medicine
IRON
|
+$57.3M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$41.5M |
| 5 |
LENZ
LENZ Therapeutics
LENZ
|
+$23.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Erasca
ERAS
$6.19B
| $29.6M | 0.84% |
13,560,017
+1,652,835
| +14% | +$2.63M |
|
27
EyePoint Inc
EYPT
$1.04B
| $28.6M | 0.81% |
+2,005,365
| New | +$23.1M |
|
|
MRUS
28
CALL
DELISTED
Merus
MRUS
| $28.2M | 0.8% |
+300,000
| New | +$19.5M |
|
29
Tango Therapeutics
TNGX
$4.43B
| $25.9M | 0.74% |
+3,086,184
| New | +$20.9M |
|
30
Amylyx Pharmaceuticals
AMLX
$2.24B
| $25.8M | 0.73% |
+1,900,000
| New | +$17.9M |
|
31
Spyre Therapeutics
SYRE
$8.24B
| $24.6M | 0.7% |
1,467,266
-403,179
| -22% | -$6.57M |
|
32
Dyne Therapeutics
DYN
$4.71B
| $24M | 0.68% |
+1,898,950
| New | +$21.7M |
|
|
BBOT
33
BridgeBio Oncology
BBOT
$661M
| $21.6M | 0.61% |
+1,866,141
| New | +$19.4M |
|
|
34
Disc Medicine
IRON
$2.93B
| $16.4M | 0.47% |
247,716
-963,255
| -80% | -$57.3M |
|
35
Structure Therapeutics
GPCR
$3.44B
| $10.4M | 0.3% |
+372,869
| New | +$7.43M |
|
|
36
CALL
Agios Pharmaceuticals
AGIO
$1.82B
| $8.03M | 0.23% |
+200,000
| New | +$7.52M |
|
|
CBIO
37
Crescent Biopharma
CBIO
$552M
| – | – |
-642,721
| Closed | -$10.4M |
|
38
Immatics
IMTX
$1.23B
| – | – |
-3,144,157
| Closed | -$16.9M |
|
|
39
MoonLake Immunotherapeutics
MLTX
$1.48B
| – | – |
-878,323
| Closed | -$41.5M |
|
|
YMAB
40
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-4,236,346
| Closed | -$19.1M |
|
|
ONC
41
BeOne Medicines Ltd
ONC
$32.6B
| – | – |
-347,787
| Closed | -$84.2M |
|
Similar funds
KCM
DGI
FC
MCM
MCCA
SIA
SCA
SMFG
Paradigm Biocapital Advisors's Q3 2025 Portfolio in Review
As of Q3 2025, Paradigm Biocapital Advisors held 41 positions worth $3.52B, up 50% from $2.34B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Paradigm Biocapital Advisors deployed $333M of net new capital in Q3 2025, opening 13 new positions and adding to 13 existing holdings. Its largest new stake was Abivax: 1,564,196 shares worth $133M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Cogent Biosciences, an estimated $85.3M trimmed.
- Paradigm Biocapital Advisors's largest Q3 2025 buy was Abivax: 1,564,196 shares worth $133M.
- Paradigm Biocapital Advisors added most to Agios Pharmaceuticals in Q3 2025, an estimated $57.6M increase.
- Paradigm Biocapital Advisors's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $85.3M.
- Paradigm Biocapital Advisors fully exited BeOne Medicines Ltd in Q3 2025, selling an estimated $84.2M.
- Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $3.52B portfolio in Q3 2025.
- Paradigm Biocapital Advisors opened 13 new positions and closed 5 in Q3 2025.
- Paradigm Biocapital Advisors's portfolio value rose 50% quarter-over-quarter to $3.52B.
Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.